<DOC>
	<DOCNO>NCT02822495</DOCNO>
	<brief_summary>This multicenter expand access protocol provide human leukocyte antigen ( HLA ) partially-matched third-party allogeneic EBV-CTLs treatment EBV-associated viremia disease comparable satisfactory alternative therapy treat patient 's disease condition . Patients must eligible enroll clinical trial design support development marketing approval Atara EBV-CTLs .</brief_summary>
	<brief_title>Study Allogeneic EBV-CTLs EBV-Associated Viremia Malignancies</brief_title>
	<detailed_description>This multicenter expand access protocol provide human leukocyte antigen ( HLA ) partially-matched third-party allogeneic EBV-CTLs treatment EBV-associated viremia disease comparable satisfactory alternative therapy treat patient 's disease condition . Patients must eligible enroll clinical trial design support development marketing approval Atara EBV-CTLs . Allogeneic third-party EBV-CTL select patient bank available EBV-CTL cell product lot base partial HLA match appropriate HLA restriction share EBV-CTL donor patient 's EBV associate viremia/disease patient , appropriate disease set . EBV-CTLs administered cycle last 5 week ( 35 day ) . During cycle , patient receive intravenous ( IV ) EBV-CTLs Days 1 , 8 , 15 , follow observation period complete 35-day cycle .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<criteria>1 . Any following diagnosis EBVassociated disease : 1 . EBV+ posttransplant lymphoproliferative disease ( PTLD ) allogeneic hematopoietic cell transplant ( alloHCT ) solid organ transplant ( SOT ) 2 . EBVassociated lymphoproliferative disorder ( LPD ) associate congenital acquire immunodeficiency 3 . EBVassociated lymphomas LPDs associate immunodeficiency ( biopsy require ) ( eg , EBV+ diffuse large B cell lymphoma ( DLBCL ) elderly ) 4 . Other EBVassociated malignancy ( biopsy require ) include nasopharyngeal carcinoma , EBV+ gastric cancer , EBV+ leiomyosarcoma 5 . EBV+ hemophagocytic lymphohistiocytosis ( HLH ) 6 . Persistent EBV viremia 2 . Evidence EBV positivity follow : 1 . Biopsy show EBV+ disease ( strongly recommend unless require , noted criterion # 1 ) , OR 2 . A combination circulate EBV DNA AND radiographic appearance consistent EBV+ malignancy , biopsy clinically feasible , unless require per criterion # 1 , OR 3 . For EBV viremia , fulfillment inclusion criterion 1f 3 . Availability appropriate HLA partiallymatched restrict EBVCTLs 4 . No approved alternative therapy available treatment EBV+ viremia/disease 5 . Not eligible trial support development Atara EBVCTLs 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 3 patient age &gt; 16 year ; Lansky score ≥ 20 patient ≤ 16 year 7 . For patient PTLD alloHCT set , underlie disease alloHCT transplant perform morphologic remission 8 . Adequate organ function per follow ( unless deem caused underlying EBVdriven process EBVCTLs intend treat , prior therapy ) : 1 . Absolute neutrophil count ≥ 500/μL , without cytokine support 2 . Platelet count ≥ 50,000/μL , without transfusion support ; platelet count &lt; 50,000/μL ≥ 20,000/μL , without transfusion support , permissible patient Grade ≥ 2 bleeding prior 6 month ( grade bleeding determine per National Cancer Institute 's Common Terminology Criteria Adverse Events [ CTCAE ] , version 4.03 ) . 3 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3× upper limit normal ( ULN ) total bilirubin &lt; 2.5×ULN ; value 5×ULN ALT , AST , and/or total bilirubin acceptable elevation consider due EBVassociated disease involvement liver 4 . Creatinine &lt; 3×ULN 9 . Patient patient 's representative willing able provide write informed consent 1 . Any investigational therapy receive ≤ 4 week prior Cycle 1 Day 1 ( coenrollment noninterventional study study sample collection permit ) 2 . Ongoing need methotrexate extracorporeal photopheresis ; steroid dos &gt; 0.5 mg/kg , prednisone equivalent , require discussion medical monitor 3 . Need vasopressor ventilatory support , unless deem cause EBVdriven process EBVCTLs intend treat 4 . Antithymocyte globulin , alemtuzumab , similar antiT cell antibody therapy , T cell therapy ( donor lymphocyte infusion , cytotoxic T lymphocytes ) ≤ 4 week prior Cycle 1 Day 1 5 . Pregnancy , except , opinion investigator consultation medical monitor , risk/benefit EBVCTL therapy favor proceed 6 . Female childbearing potential male female partner childbearing potential unwilling use highly effective method contraception 7 . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Epstein-Barr Virus</keyword>
	<keyword>Epstein-Barr Viremia</keyword>
	<keyword>Post Transplant Lymphoproliferative Disorder</keyword>
	<keyword>EBV-PTLD</keyword>
	<keyword>Solid Organ Transplant</keyword>
	<keyword>Hematopoietic Cell Transplant</keyword>
	<keyword>primary immunodeficiency</keyword>
	<keyword>acquire immunodeficiency</keyword>
	<keyword>Epstein-Barr Virus Lymphoma</keyword>
</DOC>